Background Diabetic Retinopathy

Categories: Eye diseases

Aliases & Classifications for Background Diabetic Retinopathy

MalaCards integrated aliases for Background Diabetic Retinopathy:

Name: Background Diabetic Retinopathy 12 15
Non Proliferative Diabetic Retinopathy 12
Non-Proliferative Diabetic Retinopathy 12
Nonproliferative Diabetic Retinopathy 73


External Ids:

Disease Ontology 12 DOID:13208
ICD9CM 35 362.01 362.03
UMLS 73 C0004606

Summaries for Background Diabetic Retinopathy

MalaCards based summary : Background Diabetic Retinopathy, also known as non proliferative diabetic retinopathy, is related to microvascular complications of diabetes 1 and severe nonproliferative diabetic retinopathy. An important gene associated with Background Diabetic Retinopathy is TLR9 (Toll Like Receptor 9), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Differentiation Pathway. The drugs Bevacizumab and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and endothelial, and related phenotype is digestive/alimentary.

Related Diseases for Background Diabetic Retinopathy

Diseases related to Background Diabetic Retinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 32.3 ANGPT2 VEGFA
2 severe nonproliferative diabetic retinopathy 31.5 ALB INS VEGFA
3 microvascular complications of diabetes 5 28.9 ALB ANGPT2 INS VEGFA
4 hypoglycemic coma 10.7 INS VEGFA
5 juvenile nasopharyngeal angiofibroma 10.6 TLR9 VEGFA
6 rubeosis iridis 10.6 INS VEGFA
7 keratitis, hereditary 10.4 TLR9 VEGFA
8 pyogenic granuloma 10.3 ANGPT2 VEGFA
9 female reproductive system disease 10.3 INS TLR9 VEGFA
10 poems syndrome 10.3 ANGPT2 VEGFA
11 lipodermatosclerosis 10.3 ANGPT2 VEGFA
12 macular holes 10.3 ANGPT2 VEGFA
13 epileptic encephalopathy, childhood-onset 10.2 ANGPT2 VEGFA
14 limb ischemia 10.1 ANGPT2 VEGFA
15 placental insufficiency 10.1 ANGPT2 VEGFA
16 acroosteolysis 10.1 ALB VEGFA
17 hypertensive nephropathy 10.1 ALB VEGFA
18 gastric lymphoma 10.1 ALB VEGFA
19 burns 10.1 ALB INS
20 legionnaires' disease 10.0 ALB TLR9
21 autoimmune disease of urogenital tract 10.0 ALB TLR9
22 fetal erythroblastosis 10.0 ALB INS
23 noma 10.0 ALB INS
24 autonomic nervous system disease 10.0 ALB INS
25 meningoencephalitis 10.0 ALB TLR9
26 hydrops, lactic acidosis, and sideroblastic anemia 10.0 ALB VEGFA
27 keratoconjunctivitis sicca 10.0 ALB TLR9
28 prediabetes syndrome 10.0 ALB INS
29 hepatopulmonary syndrome 10.0 ALB VEGFA
30 intermittent claudication 9.9 ALB VEGFA
31 common cold 9.9 ALB TLR9
32 leukocyte disease 9.9 ALB TLR9
33 microvascular complications of diabetes 3 9.9 ALB INS
34 ovarian hyperstimulation syndrome 9.8 ALB VEGFA
35 filariasis 9.8 ALB TLR9
36 retinitis 9.8
37 endotheliitis 9.8
38 gastrointestinal system cancer 9.7 ALB TLR9 VEGFA
39 severe pre-eclampsia 9.7 ALB VEGFA
40 glucose metabolism disease 9.7 ALB INS TLR9
41 urinary system disease 9.7 ALB INS TLR9
42 myeloma, multiple 9.7 ALB TLR9 VEGFA
43 acquired metabolic disease 9.7 ALB INS TLR9
44 exudative vitreoretinopathy 1 9.7 ANGPT2 VEGFA
45 bacterial meningitis 9.6 ALB TLR9
46 vascular disease 9.5 ALB INS VEGFA
47 arteries, anomalies of 9.3 ALB INS TLR9 VEGFA
48 nervous system disease 9.3 ALB INS TLR9 VEGFA
49 brain edema 9.2 ALB VEGFA
50 retinal vascular disease 9.0 ALB ANGPT2 INS VEGFA

Graphical network of the top 20 diseases related to Background Diabetic Retinopathy:

Diseases related to Background Diabetic Retinopathy

Symptoms & Phenotypes for Background Diabetic Retinopathy

MGI Mouse Phenotypes related to Background Diabetic Retinopathy:

# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.02 ALB ANGPT2 INS TLR9 VEGFA

Drugs & Therapeutics for Background Diabetic Retinopathy

Drugs for Background Diabetic Retinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2 347396-82-1 459903
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 59-30-3 6037
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
Pyridoxal Approved, Nutraceutical Phase 4 66-72-8 1050
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
Glucosamine Approved, Investigational, Nutraceutical Phase 4 3416-24-8 439213
11 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
12 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
13 Hematinics Phase 4
14 Micronutrients Phase 4,Phase 2,Phase 1
15 Trace Elements Phase 4,Phase 2,Phase 1
16 Vitamin B 12 Phase 4
17 Vitamin B 6 Phase 4
18 Vitamin B Complex Phase 4,Phase 1,Phase 2
19 Vitamins Phase 4,Phase 2,Phase 1,Not Applicable
20 Hypoglycemic Agents Phase 4,Phase 3
21 insulin Phase 4,Phase 3,Not Applicable
22 Insulin, Globin Zinc Phase 4,Phase 3,Not Applicable
23 Antimetabolites Phase 4,Phase 3
24 Hypolipidemic Agents Phase 4,Phase 3
25 Lipid Regulating Agents Phase 4,Phase 3
26 Anticoagulants Phase 4
27 Fibrinolytic Agents Phase 4,Phase 2
28 Glucuronyl glucosamine glycan sulfate Phase 4
Cobalamin Nutraceutical Phase 4 13408-78-1 6438156
30 Folate Nutraceutical Phase 4,Phase 1,Phase 2
31 Vitamin B12 Nutraceutical Phase 4
32 Vitamin B9 Nutraceutical Phase 4,Phase 1,Phase 2
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
Nepafenac Approved, Investigational Phase 3 78281-72-8 151075
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
Fenofibrate Approved Phase 3 49562-28-9 3339
Simvastatin Approved Phase 3 79902-63-9 54454
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
Ruboxistaurin Investigational Phase 3 202260-21-7, 169939-94-0 153999
41 Analgesics Phase 3
42 Analgesics, Non-Narcotic Phase 3
43 Antiemetics Phase 3,Phase 2
44 Anti-Inflammatory Agents Phase 3,Phase 2
45 Anti-Inflammatory Agents, Non-Steroidal Phase 3
46 Antineoplastic Agents, Hormonal Phase 3,Phase 2
47 Antirheumatic Agents Phase 3
48 Autonomic Agents Phase 3,Phase 2
49 Gastrointestinal Agents Phase 3,Phase 2
50 glucocorticoids Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
2 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
3 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
4 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
5 Avastin for Post-Photocoagulation Macular Edema Completed NCT00801866 Phase 4 Bevacizumab
6 CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea Recruiting NCT02874313 Phase 4 Pharmacological treatment
7 Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap Recruiting NCT02521116 Phase 4
8 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Not yet recruiting NCT02834663 Phase 4 Lucentis
9 A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects Unknown status NCT00908778 Phase 3 Vitreosolve;Vitreosolve
10 Nepafenac Once Daily for Macular Edema - Study 2 Completed NCT01872611 Phase 3 Nepafenac Ophthalmic Suspension, 0.3%;Prednisolone acetate
11 Nepafenac Once Daily for Macular Edema - Study 1 Completed NCT01853072 Phase 3 Nepafenac Ophthalmic Suspension, 0.3%;Prednisolone acetate
12 Intravitreal Bevacizumab for Diabetic Retinopathy Completed NCT00600262 Phase 2, Phase 3 intravitreal bevacizumab
13 Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study) Completed NCT00542178 Phase 3 Hypoglycemic Agents;Standard glycemia control;Intensive BP treatment;Standard BP control;Fenofibrate;Simvastatin;Placebo
14 Reduction in the Occurrence of Center-Involved Diabetic Macular Edema Completed NCT00090519 Phase 3 ruboxistaurin;placebo
15 Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema Completed NCT00444600 Phase 3 Triamcinolone Acetonide + laser;Ranibizumab + laser;Sham injection + laser;Ranibizumab + deferred laser
16 Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement Completed NCT01783886 Phase 3
17 PROMINENT-Eye Ancillary Study (Protocol AD) Recruiting NCT03345901 Phase 3 Pemafibrate;Placebo
18 Treatment for CI-DME in Eyes With Very Good VA Study Recruiting NCT01909791 Phase 3 Prompt aflibercept;Deferred aflibercept
19 Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) Active, not recruiting NCT02718326 Phase 3 Intravitreal aflibercept injection [IAI];Sham
20 Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy Active, not recruiting NCT02388984 Phase 3 Compound danshen dripping pills;Placebo
21 Anti-VEGF Treatment for Prevention of PDR/DME Active, not recruiting NCT02634333 Phase 3 Prompt aflibercept;Deferred aflibercept
22 Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy Terminated NCT00248131 Phase 3 Octreotide acetate in microspheres
23 Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy Terminated NCT00248157 Phase 3 Octreotide acetate in microspheres
24 A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects Terminated NCT00664183 Phase 2, Phase 3 Vitreosolve
25 Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab Unknown status NCT01845844 Phase 1, Phase 2 Ranibizumab 0.3mg/0.05cc
26 Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy Completed NCT02062034 Phase 2 Ubiquinone;Combined antioxidant therapy;Placebo
27 A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy Completed NCT02435862 Phase 2 1.0mg Luminate®;2.0mg Luminate®;3.0mg Luminate®
28 Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy Completed NCT00917553 Phase 2 doxycycline monohydrate;Placebo
29 Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment Completed NCT00198471 Phase 2 Vitrase
30 Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema Completed NCT01571232 Phase 2 dexamethasone intravitreal implant;intravitreal bevacizumab
31 A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated. Recruiting NCT03238963 Phase 2 BI 1467335;Placebo
32 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy Recruiting NCT03006081 Phase 2 Intravitreal Aflibercept injection
33 The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) Active, not recruiting NCT03197870 Phase 2 AKB-9778;Placebo
34 A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR Active, not recruiting NCT02681809 Phase 2 ocriplasmin 0.0625mg;ocriplasmin 0.125mg;Sham injection
35 Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) Active, not recruiting NCT01552408 Phase 1, Phase 2 0.3 mg ranibizumab
36 A Study of Keluo Xin Capsule Compare to Placebo in Terms of Efficacy and Safety in Patients With Diabetic Retinopathy Not yet recruiting NCT03258242 Phase 2 Keluo Xin capsule;Placebo oral capsule
37 The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy Suspended NCT01880372 Phase 1, Phase 2
38 Panretinal Photo-stimulation in Proliferative Diabetic Retinopathy Unknown status NCT02309502 Not Applicable
39 Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus Unknown status NCT01107132
40 Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography Unknown status NCT01790945
41 Study on Tear Proteins in Diabetic Retinopathy of Type 2 Diabetics Unknown status NCT00698698
42 Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER) Completed NCT01440660
43 Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2 Completed NCT00763802
44 Identifying Progression of Retinal Disease in Eyes With NPDR in Diabetes Type 2 Using Non-invasive Procedures Completed NCT01145599
45 Computer Detection of Diabetic Retinopathy Compared to Clinical Examination Completed NCT01625598
46 Diabetes Visual Function Supplement Study Completed NCT01646047 Not Applicable
47 Observational Study of DME Following Scatter Laser Photocoagulation Completed NCT00687154 Not Applicable
48 Neurovascular Coupling in Patients With Early Stage Diabetes Retinopathy Completed NCT00712842
49 Evaluation of Blood-retinal Barrier Functional Alterations by Optical Coherence Tomography Completed NCT01220804
50 Smartphone-based Ophthalmoscopy Completed NCT02177747 Not Applicable

Search NIH Clinical Center for Background Diabetic Retinopathy

Genetic Tests for Background Diabetic Retinopathy

Anatomical Context for Background Diabetic Retinopathy

MalaCards organs/tissues related to Background Diabetic Retinopathy:

Eye, Liver, Endothelial, Testes

Publications for Background Diabetic Retinopathy

Articles related to Background Diabetic Retinopathy:

(show all 11)
# Title Authors Year
The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010. ( 23551550 )
From minimal background diabetic retinopathy to profuse sight threatening vitreoretinal haemorrhage: management issues in a case of pregestational diabetes and pregnancy. ( 12873299 )
Massive subretinal bleed in a patient with background diabetic retinopathy and on treatment with warfarin. ( 12855977 )
Background diabetic retinopathy in Harare, Zimbabwe. ( 10448253 )
Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. ( 9519746 )
Contrast sensitivity changes in background diabetic retinopathy. ( 2013027 )
Does increased platelet aggregation have a prognostic value in the deterioration of background diabetic retinopathy? The Damad Study Group. ( 2270529 )
Treatment of background diabetic retinopathy. ( 3508804 )
Pattern electroretinograms become abnormal when background diabetic retinopathy deteriorates to a preproliferative stage: possible use as a screening test. ( 3964635 )
Blood pressure and the progression of mild background diabetic retinopathy. ( 4077241 )
Effect of pure O2-breathing on retinal blood flow in normals and in patients with background diabetic retinopathy. ( 6690224 )

Variations for Background Diabetic Retinopathy

Expression for Background Diabetic Retinopathy

Search GEO for disease gene expression data for Background Diabetic Retinopathy.

Pathways for Background Diabetic Retinopathy

GO Terms for Background Diabetic Retinopathy

Cellular components related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.13 ALB INS ITIH2
2 extracellular region GO:0005576 9.1 ALB ANGPT2 INS ITIH2 TLR9 VEGFA

Biological processes related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.13 ALB INS ITIH2
2 positive regulation of protein autophosphorylation GO:0031954 8.62 INS VEGFA

Sources for Background Diabetic Retinopathy

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....